MX9708418A - Moleculas de proteina modificada con mielina. - Google Patents

Moleculas de proteina modificada con mielina.

Info

Publication number
MX9708418A
MX9708418A MX9708418A MX9708418A MX9708418A MX 9708418 A MX9708418 A MX 9708418A MX 9708418 A MX9708418 A MX 9708418A MX 9708418 A MX9708418 A MX 9708418A MX 9708418 A MX9708418 A MX 9708418A
Authority
MX
Mexico
Prior art keywords
polypeptides
plp
useful
modified
mbp
Prior art date
Application number
MX9708418A
Other languages
English (en)
Other versions
MXPA97008418A (es
Inventor
John P Mueller
Michael J Lenardo
Henry F Mcfarland
Louis Matis
Eileen Elliott Mueller
Steven H Nye
Clara M Pelfrey
Stephen P Squinto
James A Wilkins
Original Assignee
Alexion Pharma Inc
Los Estados Unidos De Norteame
Representado Por El Secretario
Departamento De Salud Y Servic
Humanos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/431,644 external-priority patent/US7041503B2/en
Application filed by Alexion Pharma Inc, Los Estados Unidos De Norteame, Representado Por El Secretario, Departamento De Salud Y Servic, Humanos filed Critical Alexion Pharma Inc
Publication of MX9708418A publication Critical patent/MX9708418A/es
Publication of MXPA97008418A publication Critical patent/MXPA97008418A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Las composiciones y métodos proporcionados para la valoracion, diagnostico y tratamiento clínicos de esclerosis multiple. Las composiciones de la invencion son moléculas relacionadas con la proteína humana(PLP) y/o la proteína básica de mielina humana (MBP), e incluye ácidos nucleicos y polipeptidos. Las moléculas de ácidos nucleicos de al invencion son usados para la produccion de polipeptidos PLP modificados y polipeptidos MBP modificados, tales polipeptidos siendo usados para analizar las células T para al capacidad de respuesta a los eptitopos PLP y MBP. Los polipeptidos de al invencion son también usados como agentes, terapéuticos que actuan al inducir las respuestas de la célula T, incluyendo la energía y apoptosis, como un medio de tratamiento de la esclerosis multiple.
MXPA/A/1997/008418A 1995-05-02 1997-10-31 Moleculas de proteina modificada con mielina MXPA97008418A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US43164895A 1995-05-02 1995-05-02
US431648 1995-05-02
US08/431,644 US7041503B2 (en) 1995-05-02 1995-05-02 Modified myelin basic protein molecules
US08431644 1995-05-02
US48211495A 1995-06-07 1995-06-07
US482114 1995-06-07

Publications (2)

Publication Number Publication Date
MX9708418A true MX9708418A (es) 1998-10-31
MXPA97008418A MXPA97008418A (es) 1999-01-11

Family

ID=

Also Published As

Publication number Publication date
ATE382366T1 (de) 2008-01-15
WO1996034622A1 (en) 1996-11-07
EP0830139A4 (en) 2001-10-10
DE69637391D1 (de) 2008-02-14
JPH11511650A (ja) 1999-10-12
EP0830139A1 (en) 1998-03-25
DE69637391T2 (de) 2008-08-14
AU5565896A (en) 1996-11-21
CA2218858A1 (en) 1996-11-07
EP0830139B1 (en) 2008-01-02
KR100682350B1 (ko) 2008-11-06
KR19990008329A (ko) 1999-01-25

Similar Documents

Publication Publication Date Title
EP0830139A4 (en) MODIFIED MYELIN PROTEIN MOLECULES
WO1998027227A3 (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
NO982794D0 (no) Diagnostisering og behandling av AUR-1 og/eller AUR-2 relaterte lidelser
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
DE69739478D1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
FI964284A0 (fi) Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE69228997T2 (de) Menschliche il-3-varianten
AU7564396A (en) Rac-proteine kinase as therapeutic agent or in diagnostics
DE69535673D1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
DE69329656D1 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
ATE253117T1 (de) Adenovirus e4 proteine für induktion von zelltod
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
WO2000008157A3 (en) Human anion transporter genes atnov
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
HUP0001057A2 (hu) A szarvasmarhafélék laktációjával összefüggő fehérje (CD14), az azt kódoló gén és a fehérje B-sejt-aktiválásban való alkalmazása
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
ATE317021T1 (de) Antisense modulierung von lfa-3
DE69734890D1 (de) Rdgb-proteine
IL131436A0 (en) Compositions for treatment of disorders involving programmed cell death